InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-16 | 2026-04-16 | Cruickshank Tim | CFO | Purchase | 31.3K | $0.80 | $25K | 72.2K | View ↗ | |
| 2026-04-16 | 2026-04-16 | Elfrink Willem | Director | Purchase | 187.5K | $0.80 | $150K | 538.7K | View ↗ | |
| 2026-04-16 | 2026-04-16 | Ferrari Richard | Director | Purchase | 62.5K | $0.80 | $50K | 291.6K | View ↗ | |
| 2026-04-16 | 2026-04-16 | ENO Robert Paul | President | Purchase | 12.5K | $0.80 | $10K | 36.7K | View ↗ | |
| 2026-04-16 | 2026-04-16 | Ortigas-Wedekind Marga | Director | Purchase | 25.0K | $0.80 | $20K | 137.3K | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| General and administrative | $7.7M-13.0% | $8.8M+3.8% | $8.5M+15.8% | $7.4M |
| Research and development | $13.4M+21.7% | $11.1M+62.6% | $6.8M+19.7% | $5.7M |
| Total operating expenses | $21.1M+6.3% | $19.9M+29.9% | $15.3M+17.5% | $13.0M |
| Loss from operations | -$21.1M-6.3% | -$19.9M-29.9% | -$15.3M-17.5% | -$13.0M |
| Interest income | $122K-72.6% | $446K-33.9% | $675K+922.7% | $66K |
| Other income and expense (net) | $2K+128.6% | -$7K | $0-100.0% | $3K |
| Total other income | $124K-71.8% | $439K-35.0% | $675K+878.3% | $69K |
| Loss before provision for income taxes | -$21.0M-8.1% | -$19.4M-32.9% | -$14.6M-12.9% | -$13.0M |
| Income tax provision | $0 | $0 | $0 | $0 |
| Net Loss | -$21.0M-8.1% | -$19.4M-32.9% | -$14.6M-12.9% | -$13.0M |
| Net loss per share, basic (in dollars per share) | -$0.62+15.1% | -$0.73-1.4% | -$0.72+54.7% | -$1.59 |
| Net loss per share, diluted (in dollars per share) | -$0.62+15.1% | -$0.73-1.4% | -$0.72+54.7% | -$1.59 |
| Weighted average common shares outstanding, basic (in shares) | $33.7M+26.5% | $26.6M+31.0% | $20.3M+148.9% | $8.2M |
| Weighted average common shares outstanding, diluted (in shares) | $33.7M+26.5% | $26.6M+31.0% | $20.3M+148.9% | $8.2M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
HeartBeam (BEAT) Study Shows Portable ECG Device Can Help Identify Heart Attack Risk
Aggressive Insider Buying Signals Opportunity in 3 Risky Stocks
HeartBeam Announces New Peer-Reviewed Article Demonstrating Potential to Help Identify Heart Attack Risk at Home
HeartBeam (BEAT) Upgraded to Buy: Here's What You Should Know